Antiseptic cap with thread cover.
Abstract
La presente invención se refiere a un montaje de jeringa (10) que incluye: (1) un barril de jeringa (14) que define una cámara (18); (2) un émbolo (12) montado en la cámara (18) y movible con respecto al barril (14); y (3) un montaje de tapa (80) que contiene una tapa (82) y un material absorbente (86) que es unido de manera removible al émbolo.

Term
3.3 yearsleft in the term
Expires 7 January 2030.
- Priority
- Filed
- Granted
- Today
- Expires
26 claims: 6 independent, 20 dependent
- 1REIVINDICACIONES Habiéndose descrito la invención como antecede se reclama como propiedad lo contenido en las siguientes reivindicaciones:1. Un ensamble de tapa antiséptica para usarse con un ensamble de émbolo, el ensamble de tapa antiséptica comprende: un soporte de tapa que comprende: una primera pared anular que define una primera cámara y un eje longitudinal, la primera pared anular tiene una primera superficie interior y una primera superficie externa, y una o más extremidades de retención;y una tapa antiséptica que comprende: una segunda pared anular que define una segunda cámara, la segunda pared anular tiene un primer extremo, un segundo extremo, una segunda superficie interior, y una segunda superficie externa, un agente antiséptico dentro de la segunda cámara, una o más extremidades axiales, y una cubierta de rosca en el primer extremo de la segunda pared anular, en donde la tapa antiséptica es recibida de manera removible dentro de la primera cámara. T > F 7·'. 7 £ 1'0 £' £ INSTITUTO MEXICANO ' DE LA Ι·ΚΟΙ(.ΟΑΟ V'·.- ... INÜUmtiL * J ~. \ El ensamble de tapa antiséptica de conformidad i
- 2con la reivindicación 1, caracterizado porque una o más de la una o más extremidades de retención del soporte de tapa están configuradas para interactuar con una o más de la una o más extremidades axiales de la tapa antiséptica para limitar movimiento giratorio relativo entre el soporte de tapa y la tapa antiséptica.
- 3El ensamble de tapa antiséptica de conformidad con la reivindicación 2, caracterizado porque el soporte de tapa incluye uno o más elementos de retención dispuestos sobre la primera superficie externa.
- 4El ensamble de tapa antiséptica de conformidad con la reivindicación 3, caracterizado porque uno o más del uno o más elementos de retención están configurados para resistir pero no prevenir movimiento axial relativo entre el soporte de tapa y un émbolo.
- 5El ensamble de tapa antiséptica de conformidad con la reivindicación 4, caracterizado porque el uno o más elementos de retención incluyen una o más extremidades axiales.
- 6El ensamble de tapa antiséptica de conformidad con la reivindicación 5, caracterizado porque uno o más de la una o más extremidades axiales están configuradas para interactuar con una o más ranuras de un émbolo.
- 7El ensamble de tapa antiséptica de conformidad ττ*. IMPI P -¾ v INSTITUTO μ£Χ.·χ> ”··< Z DE LA FFMHirAL V* · ' '/ . . , . . , industrial con la reivindicación 4, caracterizado porque uno o maa~dél uno o más elementos de retención comprendé una 1 piuLubetaitei-a-^-*· anular.
- 8El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la segunda cámara aloja un material absorbente que retiene de manera liberable el agente antiséptico.
- 9El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque una porción de la segunda superficie interior es revestida con el agente antiséptico.
- 10El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la tapa está configurada para permanecer unida a un sitio de acceso después que se remueve la tapa de la primera cámara.
- 11El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la tapa de rosca está configurada para retener el agente antiséptico dentro de la segunda cámara cuando la tapa antiséptica está en uso.
- 12El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la tapa de rosca está configurada para prevenir entrada de contaminantes dentro de la segunda cámara cuando la tapa antiséptica está en uso. IΜ ΡI instituto mexicano yoT'. ,< A J DE LA rROriEDAD ’ζ\Q
- 13El ensamble de tapa antiséptica d¿ f ' ;D bÓtt'f ormindda^*· con la reivindicación 1, caracterizado poique se—f^rtna^urr.^^ sello por la cubierta de rosca cuando la tapa antiséptica está en uso.
- 14El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque el soporte de tapa además comprende un sello removible configurado para limitar evaporación del agente antiséptico de la tapa antiséptica.
- 15El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la una o más extremidades de retención se extienden perpendiculares al eje longitudinal.
- 16El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la una o más extremidades de retención se extienden radialmente hacia afuera y axialmente a lo largo de la primera superficie externa en intervalos regulares alrededor de la primera pared anular.
- 17El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque la una o más extremidades axiales se extienden radialmente hacia afuera y axialmente a lo largo de la segunda superficie externa en intervalos regulares alrededor de la segunda pared anular.
- 18El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque además comprende una tiene una varilla de émbolo, ía* varilla de émbolo tiene primer extremo y un segundo extremo opuesto al primer extremo, en donde el soporte de tapa se coloca dentro del primer extremo.
- 19Un método para limpiar y cubrir un sitio de acceso, el método caracterizado porque comprende las etapas de:proporcionar el ensamble de tapa antiséptica de conformidad con la reivindicación 1;unir la tapa antiséptica sobre un sitio de acceso;permitir que la cubierta de rosca haga contacto con el sitio de acceso;y retirar el soporte de tapa de la tapa antiséptica al mover el soporte de tapa lejos del sitio de acceso.
- 20El método de conformidad con la reivindicación 19, caracterizado porque remover el soporte de tapa permite que la tapa antiséptica permanezca sobre y cubra el sitio de acceso.
- 21El método de conformidad con la reivindicación 19, caracterizado porque la etapa de unir la tapa antiséptica incluye la etapa de prevenir movimiento giratorio relativo entre el soporte de tapa y la tapa antiséptica para asegurar movimiento giratorio común alrededor del eje longitudinal.
- 22El método de conformidad con la reivindicación INSTITUTO MEXICANO Df LA PROPIEDAD 19, caracterizado porque ademas comprende ponespuseni el sitio de acceso con un material absorhant-A que y^tiene de manera liberable el agente antiséptico, en donde el material absorbente está alojado dentro de la tapa antiséptica.
- 23El método de conformidad con la reivindicación 22, caracterizado porque además comprende retener el agente antiséptico dentro de la segunda cámara cuando la cubierta de rosca se acopla con el sitio de acceso.
- 24El método de conformidad con la reivindicación 19, caracterizado porque además comprende remover un sello del ensamble de tapa antiséptica.
- 25El ensamble de tapa antiséptica de conformidad con la reivindicación 1, caracterizado porque el agente antiséptico está impregnado en la segunda pared anular.
- 26Un ensamble de émbolo equipado con tapa antiséptica, caracterizado porque comprende:una varilla de émbolo que tiene un primer extremo y segundo extremo opuesto al primer extremo, el primer extremo tiene un alojamiento con una primera pared que define una primera cámara;y el ensamble de tapa antiséptica de conformidad con la reivindicación 1 colocado dentro de la primera cámara.
Independent claims26
546 paragraphs in 10 sections, as filed
(54) Title: ANTISEPTIC LID WITH THREADED COVER.
(54) Title: ANTISEPTIC CAP WITH THREAD COVER.
(57) Summary
The present invention relates to an antiseptic cap assembly for use with a plunger assembly, the antiseptic cap assembly comprises: a cap holder comprising: a first annular wall defining a first chamber and a longitudinal axis, the first wall annular has a first inner surface and a first outer surface, and one or more retaining ends; and an antiseptic cap comprising: a second annular wall defining a second chamber, the second annular wall having a first end, a second end, a second inner surface, and a second outer surface, an antiseptic agent within the second chamber, one or more axial ends, and a screw cap at the first end of the second annular wall, where the antiseptic cap is removably received within the first chamber.
(57) Abstract
A syringe assembly (10) including: (1) a syringe barrel (14) defining a chamber (18); (2) a plunger (12) mounted in the chamber (18) and moveable with respect to the barrel (14); and (3) a cap assembly (80) containing a cap (82) and an absorbent material (86) is removably attached to the plunger.
PATENT TITLE No. 354573
IMPI. . . μ. Λ μ, · (, · <.11 - ..
<img file="MX354573B_D0001.tif" />
Headlines):
Home:
EXCELSIOR MEDICAL CORPORATION
1923 Heck Avenue, Neptune, New Jersey, 07753, USA
Denomination: ANTISEPTIC LID WITH THREADED COVER.
Classification:
Inventor (s):
A61M5 / 00 A6iM§ / oa<sub>s</sub> IV; ,
WILLIAM ANÜERSÓN- MARK WILSON; FÍENNIGER; LARRY COLQUITT;
CHRIST © PHER “E. GARDN
CIP:
CPC:
The patent of refere
<img file="MX354573B_D0002.tif" />
ormad
NumberX ^
MX / a / 2013/006475
Validity: WmWañ
Date
Expsdic date
In accordance with the art from the date of present
Who subscribes to this title (Official Gazette of the Federation 25/01/2006, 06/05 / 2009,06 / 01/2010, Regulations of the Mexican Institute articles 1<sup>or</sup>, 3<sup>or</sup>, 4th, 5th fraction V subsection a)
12/27/1999, amended on 10/10/2002, 07/29 / Deputy Generals, Coordinator, Departmental Directors and other subordinates of the Instituto Mexi '08/04/2004 and 09/13/2007).
e pftefffé <?
ational
Number:
11 / 821,190 12 / 2¼.526 • I t í «
I Industrial.
Λ ..
the twenty <fijtej «non-extendable, counted to current kMMMdSnerjAArecbos. téi & Br III and JR ^ sf ste the Industrial Property Law, 26/12 / '5 / .1999, 01/26/2004, 06/16/2005,
Λ a), 4 ° and 12<sup>or</sup> sections I and III of ΡΛ7 / 2004, 07/28/2004 and 09/07/2007); ino of Industrial Property (DOF or that delegates powers to the Directors. Divisional Deputy Directors, Coordinators' 12/15/1999, amended on 02/04/2000, 07/29/2004,
<img file="MX354573B_D0003.tif" />
This letter is signed with an advanced electronic signature (FIEL), based on articles 7 BIS 2 of the Industrial Property Law; 3 of its Regulations, and 1 fraction III, 2 fraction V, 26 BIS and 26 TER of the Agreement establishing the guidelines for the use of the Electronic Payment and Services Portal (PASE) of the Mexican Institute of Industrial Property, in the procedures indicated.
THE DIVISIONAL DIRECTOR OF PATENTS
<img file="MX354573B_D0004.tif" />
NAHANNY CANAL REYES
Original string:
NAHANNY MARISOL CANAL REYES | 00001000000403252793 | Administration Service
Tax | 1695 || MX / 2018/20902 | MX / a / 20l3 / 006175 | Normal patent title with divisional PCT | 1223 | GAGV | Page (s) 1 | hVPsRKVymeJ0uNof¡XLm9jD4u / Y =
Digital Seal: wq8XnSL / XpOsBAZZsl1QE6NkXiS1qj + dXn4NVWpr5fgsGnggCAbjjFgrVHt8jDAgu + Xavokf7JPHKJ5wfGYyy7Pnne Kiv0Zce73OgvefOI31UStZck9RmUzqQ¡TLgGTwsW / 3ColOfb5GrNBLZH2UkiC9JUbVelP0ofOncKKpqCw9Sav + pUfl hEk56bH2M93T00Eye5kCloGlk5vlvg2hMoK8mnY6XqQdRU + 31DcCtwNedbrUcYkhzgN3clqhwt7FAquqCzJ4jOlvV8 DPbkAtfDzzJCZ5aUZ / K / 7WrPfSCeqbSJqF / UGL7LrKR + 3 / + 3qo40poMcOhRQ4bQT3OtaA == CYO
Arenal No 550, Floor 1, Pueblo Santa María Tepepan, Xochimilco, 16020. Mexico City.
(55) 53340700 www.gob.mx/irnpi
<img file="MX354573B_D0005.tif" />
<img file="MX354573B_D0006.tif" />
Γ77
I »/
ΤΆΡΑ ANTISEPTIC WITH COVER
Field of the Invention
<img file="MX354573B_D0007.tif" />
Dfc LA Fk (_)
INDUSTKl. The present invention relates to an antiseptic cap having a threaded cap to enhance a seal between the cap and an access site to a mammalian body. More particularly the invention relates to an antiseptic cap for attaching to an access site of a central venous catheter and having a threaded cover to improve a seal between the cap and the access site.
Background of the Invention
Catheters are widely used to treat patients who require a variety of medical procedures. Catheters can be either acute, or temporary, for short-term use or chronic for long-term treatment. Catheters are commonly inserted into central vein sites (such as the peripheral vein to provide access to a patient's vascular system. Catheters offer many benefits to patients; for example, chronic catheters provide easy access without repeated punctures or repeated vessel cannulation for the administration of large volumes of fluids, nutrients, and medications and blood draw on an intermittent basis. With regard
Ref .: 241699 to the use of catheters to include the infusion of infusion drugs
IΜ p ϊ of f 1 ufcd- © is.,: Los. 'DELA examples PXCu; ·· * Ο <ν-.' ,. J
INDLS 1 bad electrolytes or fluids used in chemotherapy.
In chemotherapy, catheters are used for drug infusion on a basis ranging from daily to weekly.
intermittent,
Another example includes the use of catheters in the treatment of hyperalimentation, where catheters are usually used for infusion of large volumes of fluids.
For hemodialysis, catheters are commonly used - usually three times a week - for aspiration of blood for dialysis treatment and rapid return of blood to the circulation after treatment. Although a preferred mode of vascular access for a hemodialysis patient involves the use of an arteriovenous (AV) fistula of either the upper or lower extremities or an arteriovenous bridge graft (typically using PTFE), the use of these access devices does not it is always possible or desirable. When any of these vascular access modes are not available, for example, due to insufficient blood vessels suitable for creating AV leads or due to established AV leads that do not function optimally, a large perforation venous line catheter will typically be requires for hemodialysis.
Catheters used for hemodialysis usually include two lumens of relatively required diameter during such a large catheter (usually cast as a hemodialysis aspiration and rapid blood return procedure. One lumen for aspiration, or removal, of blood, while the other lumen is used to return blood to the patient's blood stream.
Catheter connections, such as, for example, catheter connections to dialysis machine tubing, IV line tubing, infusion ports, and catheter caps, which are used to seal the end of a catheter to protect Catheter sterility and preventing fluid loss and / or particle contamination are most often done using standardized Luer taper fittings from the medical industry. These fittings, which can be either male or female couplings, include a tapered end of standardized dimensions. The coupling is made by the press fit of the connecting parts. A lock or other type of locking mechanism is commonly used to ensure the integrity of the press fit of Luer fits.
Catheters, especially chronic venous catheters, provide challenges in their use. One challenge is that such catheters can become occluded by a thrombus. To prevent catheter clotting in dialysis blood vessels when functioning and residing within a central vein (i.e. superior vena cava, inferior vena cava, catheter lumens are frequently filled with a blocking solution of a concentrated solution of the anticoagulant commonly used heparin (up to 10,000 units of heparin per catheter lumen).
Brief Description of the Invention
As used herein, the terms "blocking solution" or "blocking solution" refers to a solution that is injected or otherwise infused into a lumen of a catheter with the intention of allowing a substantial portion of the blocking solution to remain in the lumen and not into the systemic blood circulation until access to this particular lumen is desired or required again, typically for further treatment, i.e., infusion or removal of fluid. In addition, attention has been given to the development of alternative blocking solutions with the aim of improving the permeability rates of vascular catheters. For example, lower alcohol containing blocking solutions are under development where lower alcohols include ethanol, propanol, and butanol. Anti-microbial and / or jL anticoagulant additives can optionally be added.
<img file="MX354573B_D0008.tif" />
sunscreen containing lower alcohol. Preferably, the blocking solution can remain in the lumen for a desired amount of time that lasts from about 1 hour to 3 or 4 days or longer.
For the reasons described above, significant care must be taken when infusing medications, nutrients, and the like into a catheter, and when blocking a catheter between uses, to minimize the risks associated with a permanent catheter, including the risk of thrombosis or coagulation. , the risk of excessive anticoagulation and the risk of infection. Syringes are typically used to deliver the required amount of catheter blocking solution (determined by the catheter manufacturer) into a permanent catheter after a given use. Flushing procedures also require that care be taken to prevent backflow of blood into the catheter. Reflux in IV therapy is the commonly used term to describe the fluid that is drawn back into the catheter after a rinse procedure. The thing is, the reflux fluid contains blood or solution that can cause the catheter to occlude. To ensure that reflux does not occur, the rinse procedures suggest two techniques: 1) at the end of the rinse solution supply, the user maintains pressure on the
<img file="MX354573B_D0009.tif" />
ΙΜΡϊ syringe plunger while fixing the line (NOUSTRlAl the last 0.5 ml of solution is supplied to disconnect the syringe from port IV or fix the line IV Any technique maintains positive pressure on the fluid in the catheter to prevent the backflow of fluid and blood.
In light of the problems described above, there is a continuing need for advances in catheter locking techniques, devices, and procedures to improve the safety and efficacy of catheter locking procedures and overall patient care.
Brief Description of the Figures
FIG. 1 is a perspective view of a syringe barrel and plunger assembly equipped with an antiseptic cap prior to connection of a syringe tip to an access point to a central venous catheter;
FIG. 2 is a perspective view of a syringe barrel and plunger assembly equipped with an antiseptic cap with the syringe tip connected to an access point to a central venous catheter;
FIG. 3 is a perspective view of a syringe barrel and plunger assembly equipped with an antiseptic cap prior to connection of the antiseptic cap to an access point to a central venous catheter;
FIG. 4 is a perspective view of a mount
<img file="MX354573B_D0010.tif" />
after connection of the antiseptic cap to an access point to a central venous catheter;
FIG. 5 is a perspective view of the drawn assembly of a plunger equipped with an antiseptic cap;
FIG. 6 is a perspective view of a plunger equipped with an antiseptic cap in a partially assembled state;
FIG. 7 is a perspective view of the plunger equipped with antiseptic cap of FIG. 6 with a superior seal;
FIG. 8 is a perspective view of a plunger equipped with an antiseptic cap of FIG. 7 mounted on a lumen of a syringe barrel;
FIG. 9 is a side sectional view of a plunger and syringe barrel assembly equipped with an antiseptic cap.
FIG. 10 shows an exploded view of a detail of FIG. 9 of one embodiment of the syringe barrel and plunger assembly equipped with antiseptic cap;
FIG. 11 shows an exploded view of a detail of FIG. 9 from another embodiment of the syringe barrel and plunger assembly equipped with antiseptic cap;
FIGS. 12-14 show various grip modes of the plunger mount equipped with antiseptic cap;
r:
'Z.
f <
FIGS.
mounting method
1Μ? I
15-17 show varia§<sup>m</sup>D ^^ $$ '¿syringe barrel and plunger equipped with antiseptic cap with a barrel lock to resist rotation of the plunger mount relative to the syringe barrel;
FIG. 18 shows another embodiment of a barrel lock to resist rotation of a plunger mount relative to the syringe barrel;
FIGS.
19-20 show various views of another embodiment of anti-reflux syringe barrel mounting and plunger equipped with antiseptic cap with a barrel lock to resist rotation of the plunger assembly relative to the syringe barrel;
modality
FIG. 21 shows a perspective view of another of the syringe barrel and plunger assembly equipped with an antiseptic cap with a barrel lock to resist rotation of the plunger assembly relative to the syringe barrel;
FIGS.
22a-22b are respectively a perspective view of an antiseptic cap without a sponge and with a sponge;
FIGS.
and 24 are different modalities of the antiseptic cap with varied grip characteristics;
FIG. 25 is a perspective view of the antiseptic cap of FIG. 22b prior to coupling with a
<img file="MX354573B_D0011.tif" />
FIG. 26 is a perspective view of the valve cover;
<img file="MX354573B_D0012.tif" />
antiseptic of FIG. 22b coupled with a valve;
FIG. 27 is a side sectional view of the antiseptic cap and valve assembly shown in FIG. 26;
FIGS. 28-30 are side sectional views of two different modalities of the antiseptic cap;
FIGS. 31a-31b are, respectively, side sectional views showing an antiseptic cap with an actuation post centrally positioned in a valve with the valve in the inactivated and activated positions;
FIGS. 32 and 33 are side sectional views showing two different modalities of an antiseptic cap having a molded sponge;
FIG. 34 is a side sectional view showing another embodiment of an antiseptic cap having a molded sponge attached to a valve;
<td>The</td><td>FIG.</td><td> 35</td><td>is a</td><td>view</td><td>sectional</td><td>side</td><td>than</td>
<td>shows a</td><td>stage</td><td>of</td><td>join a</td><td colspan="3">sponge molded to a</td><td>top</td>
<td>antiseptic;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>The</td><td>FIG.</td><td> 36</td><td>is a</td><td>view</td><td>sectional</td><td>side</td><td>than</td>
<td>shows a</td><td>stage</td><td>of</td><td colspan="2">supply a</td><td>compound</td><td>antiseptic</td><td>co a</td>
a molded sponge positioned within a lid;
FIG. 37 shows a side sectional view of an antiseptic cap attached to a valve with the cap
<img file="MX354573B_D0013.tif" />
antiseptic having an antisiep coating ^^^^ - 'g (NDUSTlJAL
FIG. 38 shows a perspective view of an antiseptic cap in an ampoule container;
FIG. 39 is a side cross sectional view of an antiseptic cap with a threaded cover;
FIG. 40 is a side cross sectional view of an antiseptic cap with a threaded cover;
FIG. 41 is a side cross sectional view of an antiseptic cap with a threaded cover;
FIGS. 42a-42b are perspective front and rear views of an antiseptic cap with a threaded cover connected to a Cardinal SMART SITE access site;
FIGS. 43a-43b are perspective front and rear views of an antiseptic cap without a threaded cover connected to a Cardinal SMART SITE access site;
FIGS. 44a-44b are front and rear perspective views of an antiseptic cap with a threaded cover connected to a C1000 Key Hospira Access Device (ICU);
FIGS. 45a-45b are perspective front and rear views of an antiseptic cap without a screw cap connected to a C1000 Key Hospira Access Device (ICU);
FIGS. 46a-46b are perspective front and rear views of an antiseptic cap with a threaded cover connected to an access device B.
<img file="MX354573B_D0014.tif" />
FIGS. 47a-47b are perspective front and rear views of an antiseptic cap without a threaded cover connected to a B. Braun ULTRASITE access device;
FIGS. 48a-48b are front and rear perspective views of an antiseptic cap with a threaded cover connected to a Rymed INVISION PLUS access device;
FIGS. 49a-49b are perspective front and rear views of an antiseptic cap without a threaded cover connected to a Rymed INVISION PLUS access device;
FIG. 50 is a side cross sectional view of an antiseptic cap with a threaded cover connected to a Cardinal SMARTSITE PLUS access device;
FIG. 51 is a side cross sectional view of an antiseptic cap with a screw cap connected to a Cardinal SMARTSITE PLUS access device and the screw cap has a reduced diameter when compared to the screw cap shown in FIG. fifty;
FIG. 52 is a side cross sectional view of an antiseptic cap with a threaded cover connected to a Hospira C1000 access device (ICU) having a threaded cover with an alternate profile.
FIG. 53 is an assembly view of a syringe barrel and plunger system equipped with a cup holder and antiseptic cap;
FIG. 54 is an antiseptic cup-lid holder * t '; _ ·>
Assembly view,., d'é 'adjacent to a syringe barrel and plunger system;
The
FIG. 55 is a cross sectional side view of a syringe barrel and plunger assembly equipped with a cup holder and antiseptic cap;
The
FIG. 56a is a perspective view of a medical access device adjacent to a syringe barrel and plunger assembly equipped with an antiseptic cap.
FIG. 56b is a perspective view of a medical access device attached to a syringe barrel and plunger assembly equipped with an antiseptic cap;
FIG. 56c is a perspective view of a medical access device attached to an antiseptic cap adjacent to a syringe barrel and plunger assembly;
FIG. 57 is an enlarged view of an antiseptic cap and cup holder assembly adjacent to an open and empty chamber of a syringe plunger;
FIG. 58 is an enlarged view of an antiseptic cap and cup holder assembly positioned within a syringe plunger chamber;
FIG. 59 is a perspective view of an alternative embodiment of an antiseptic cap assembly adjacent to a syringe barrel and plunger assembly;
FIG. 60 is a perspective view of an alternative embodiment of a
<img file="MX354573B_D0015.tif" />
coupled to a syringe barrel and plunger mount; and
FIG. 61 is a perspective view of an alternative embodiment of an antiseptic cap assembly coupled to a syringe barrel and plunger assembly with an outer wall that is transparent to reveal the interior portions of the assembly.
Detailed description of the invention
While this invention is capable of embodiment in many different forms, the specific embodiments thereof are shown in the figures, and will be described in detail with the understanding that the present description will be considered as an exemplification of the principles of the invention and it is not intended to limit the invention to the specific embodiments illustrated.
FIGS. 1 and 2 show a syringe barrel and plunger assembly 10 equipped with an antiseptic cap having a plunger assembly 12 equipped with an antiseptic cap and a syringe barrel 14. Barrel 14 has a side wall 16 defining a chamber 18 and the Barrel has a proximal end 20 and a distal end 22. Proximal end 20 has an opening 23 to chamber 18 and a projection 24 extending radially outward from wall 16. Projection 24 has upper and lower surfaces 26, 28 and provides a gripping surface for a user
<img file="MX354573B_D0016.tif" />
distal end 22 of barrel 14 has an end wall 30 and an elongated tip 32 extending distally therefrom and having a passageway 34 therethrough and in fluid communication with chamber 18. The distal end wall 30, in a preferred embodiment of the invention, is generally conical in shape and, as is well known in the art, may have an interlocking luer collar 35 concentrically surrounding tip 32 and having a set of threads 37 on an internal surface thereof. Luer collar 35 allows attachment of a needle or cannula to barrel 14 and for coupling assembly 10 to splice threads located in other devices such as valves, injection sites, and other medical access devices well known in the art. FIG. 1 shows the syringe mount next to an access site 38 having a valve 39 that controls access to a lumen of a pipeline 41.
In a preferred embodiment of the invention chamber 18 of syringe mount 10 will be filled with a blocking solution or a rinse solution for use with a permanent central venous catheter. The way to use a catheter rinse or blocking solution is well known in the art. Suitable blocking or rinsing solutions will be described later. The rinse or blocking solution is injected into a
<img file="MX354573B_D0017.tif" />
catheter fluid access for cleaning
<img file="MX354573B_D0018.tif" />
catheter and can be removed from the catheter or allowed to remain in a final portion of the catheter to serve as a barrier to the entry of pathogens and contaminants.
The antiseptic cap plunger assembly 12 has an elongated shaft 40, a proximal end 42, and a distal end 44. The elongated shaft 40, in a preferred embodiment of the invention, is generally cruciform in cross-sectional shape. A plunger or piston 50 connects to the distal end 44 of shaft 40. Piston 50 is dimensioned such that when inserted into syringe barrel chamber 18 an outer circumferential surface of piston 50 is in fluid tight engagement with an inner surface 54 of the syringe barrel. Piston assembly 14 when moved proximally (or when withdrawn) can draw fluid into the chamber and when moved distally (or when inserted into the syringe chamber) can push fluid out of the chamber. FIG. one shows the piston assembly 14 partially inserted into the syringe chamber and FIG. 2 shows the piston mount fully inserted into the syringe chamber to supply fluid to the tubing
41.
A housing 60 is located at the proximal end of the plunger assembly 12 and has a wall 62 defining a chamber 64 having an open end 66 which is
IΜ Ρ1 ΆΑ'γINSTITUI 0mex.c-.no '#> · <-: - + · »οι La pro; ki> a ») ....“:. j '-Jf can seal by any structure or material acfectfádoΧξγΪ' '** as a cover or by a sheet metal material “ΤδΆ'ΤΓηύ<sup>J,</sup>optional annular saTTSTTbe * "" 70 extends radially outward from wall 62 and provides a surface on which the sealing structure can be attached.
FIG. 5 shows a lid assembly 80 close to chamber 64 of housing 60 and FIG. 6 shows lid assembly 80 positioned within chamber 64. In a preferred embodiment of the invention, layer assembly 80 has a lid 82 having a wall 83 defining a chamber 84 containing an absorbent material 86 such as a sponge. Sponge 86, in a preferred embodiment of the invention, is moistened or soaked with an agent such as an antiseptic, anticoagulant, or antimicrobial (antiseptic solution) and can be selected from the blocking and rinsing solutions described below or the antiseptic solutions described below . Cap 82
<td>has a</td><td>surface</td><td>interior 87</td><td>with</td><td>a</td><td>joint</td><td>of</td><td>threads</td><td> 88</td>
<td colspan="2">to mate with</td><td>a set</td><td>of</td><td colspan="2">threads on</td><td>the</td><td>site</td><td>of</td>
<td>access 38</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>FIGS.</td><td colspan="2">7 and 8 show</td><td>the</td><td>mounting</td><td>of</td><td>top</td><td> 80</td>
sealed with a sheet metal material or cover sheet material which can be attached to the projection 70 by any suitable method such as by adhesives or by conductive or inductive heat sealing techniques. FIG. 7 shows antiseptic cap piston assembly 12
<img file="MX354573B_D0019.tif" />
the piston assembly equipped with.-inf'copt · 12 __ inserted into the chamber of the syringe barrel 14 to define the syringe barrel and piston assembly equipped with antiseptic cap 10.
FIGS. 3 and 4 show a possible method of using cover assembly 80 by coupling with access device 38. FIG. 3 shows the clamped cover plate 68 of the projection 70 and FIG. 4 shows the coupling of antiseptic cap assembly 80 to valve 39. The syringe barrel is rotated clockwise or counterclockwise to engage the threads 88 of the antiseptic cap assembly 80 with the threads of the access site 38. After engagement, the syringe barrel 14 will be removed from access site 38 and antiseptic cap assembly 80 will slide out of housing 60 and remain attached to access site 38. Antiseptic cap assembly 80 can remain attached to valve 39 at access site 38 for any suitable period of time from a few minutes to numerous hours. When antiseptic cap assembly 80 is attached to valve 39 the tubing or catheter 41 is sealed to block pathogens and contaminants from entering the catheter and a portion of access site 38 is exposed to antiseptic material in the sponge
86.
I Μ P
JL ΙΛ -. . ΙΝ-ΙΊΪ'ίΓΟ
Dr La Y>. .. l> U '? uSTkí AL
<img file="MX354573B_D0020.tif" />
syringe
It is desirable that during rotation of the barrel of the antiseptic cap assembly 80 it does not rotate with respect to the housing and / or optionally that the plunger assembly 12 does not rotate with respect to the syringe barrel 14 until the threads 88 of the antiseptic cap have fully threaded access site threads 38. The present invention provides a mechanism associated with mount 10 to prevent rotation of antiseptic cap assembly 80 with respect to plunger mount 14 and more preferably a mechanism in either the plunger mount or antiseptic cap mount 80 to prevent the relative rotational motion between antiseptic cap assembly 80 and plunger assembly 12. In an even more preferred form of the invention, the mechanism for preventing relative rotation of the antiseptic cap assembly 80 with respect to the plunger assembly 12 has splice portions on both sides that when cooperatively assembled engage with each other to prevent rotation relative. It is also contemplated that a separate mechanism, device, or member may be used to interlock the two parts together to achieve this purpose.
If a user grasps the mount 10 by the plunger mount and antiseptic cap 12 then the interlocking structures between the plunger mount 12 and the syringe barrel 14 might not necessarily be needed. By
<img file="MX354573B_D0021.tif" />
<img file="MX354573B_D0022.tif" />
Accordingly, FIGS. 5, 9-11 show<sup>INC</sup>There are * ru ^ TMfe¿5 copies for interlocking the assembly from inside the housing 60 so that these parts rotate together and one part does not rotate in one direction or at a different speed from that of the other part. Furthermore, FIGS. 15-18 show exemplary structures for interlocking antiseptic cap plunger assembly 12 with syringe barrel 14.
In a preferred embodiment of the invention housing 60 will have a feature or structure that forms a tight fit with external surface 83 of antiseptic cap 80. Even more preferably, an internal surface 63 of side wall 62 of housing 60 will have a feature or structure to form a tight fit with a portion of the antiseptic cap assembly 80. In another preferred embodiment of the invention, the antiseptic cap assembly 80 will have a feature to form a tight fit with the housing 60 and even more preferably the outer surface 83 of the antiseptic cap 80 will have a feature to contact the inner surface 63 of the housing side wall 62.
In another preferred embodiment of the invention, the plunger housing 60 and the lid assembly 80 will each have a characteristic coupling structure
MIXICAN INSTITUTE cooperatively with each other to prevent the ro'Éaaíb ^ K'.lte'i ^ of the assembly of
<img file="MX354573B_D0023.tif" />
cap 80 and housing 60t—. The FTG__5_ shows ^ a preferred embodiment of the invention having a plurality of circumferentially spaced and axially extending ribs 100 on the inner surface 63 of the housing side wall to engage wall 83 of the antiseptic cap 82 to lock cap assembly 80 in place to prevent rotation of cap assembly 80 when positioned within housing 60. In a preferred embodiment of the invention, the internal ribs 100 extend from a bottom wall 102 to an intermediate height of the housing side wall 62. In a preferred embodiment of the invention, the internal ribs 100 will have a height approximately equal to one lid height 82. A plurality of internal notches 108 are defined between each set of adjacent internal ribs 100. The inner ribs 100, in a preferred embodiment of the invention, will have a width that tapers internally from near the bottom wall 102 to an upper part 104 of the inner ribs 100 so that the width of the inner ribs decreases from one part bottom 106 of a rib to top 104 of the rib. Furthermore, it is preferably that the upper part of the inner ribs 100 have a generally profile
<img file="MX354573B_D0024.tif" />
<img file="MX354573B_D0025.tif" />
INSTITUTO MEX'CAN'O arched to act as a hard entry ^ t ^ j ^ gt »: S of the antiseptic cap assembly 80 in the housing 60. _ In a preferred embodiment of the invention, the internal ribs 100 will end up short of an upper part 113 of the housing side wall 62 to define an annular opening 111 between the upper part of the rib 104 and the upper part 113. Furthermore, radially extending internally from the inner surface 63 of the cover 82 is a retainer 109 positioned proximal to an upper portion 113 of the side wall 62.
Antiseptic cap 82 has a plurality of circumferentially spaced and axially extended ribs 120 extending along an external surface 121 of wall 83 of cap 82 (external ribs 120). In a preferred embodiment of the invention, the outer ribs 120 extend between the annular protrusion 123 to a proximal end 124 of cap 82 to a position proximal to a distal end 126 of cap 82. The outer ribs 120 are dimensioned to engage a portion of the inner wall surface 63 of the housing 62 to prevent relative rotation of the cap mount 80 and the plunger mount 12. The spacing between the outer ribs defines a plurality of outer notches 122 between each adjacent pair of outer ribs 120. When the lid 82 is positioned within chamber 64 (FIGS. 9 and 11) each of the outer ribs 120
IMi
INSTITUTE ^ í.7 are positioned <sup>D £</sup>d ^ $ £<sup>!</sup>
<img file="MX354573B_D0026.tif" />
Inner notch 108 and each of the inner ribs 100 are positioned within an outer notch 122 to interlock these parts together to ensure that the cap rotates in the same direction as the plunger rod assembly 12. FIGS. 6 and 11 also show that when the cover 82 is positioned within the housing 60, the retainer 109 contacts the annular projection 123 to hold the cover assembly 80 in the piston housing chamber 64 to prevent or resist inadvertent dropping of the assembly. cover 80 of the housing chamber 64 prior to coupling the cover assembly 80 with the access site 38.
FIGS. 12-14 shows various modalities of gripping surfaces in housing 60 (with cover plate 68 removed) to facilitate use of mount 10 or plunger mount 12. FIG. 12 shows axially extended and circumferentially spaced protuberances 130 on an external surface of wall 62. The protuberances 130 can have numerous different cross-sectional shapes including circular, polygonal, oval and irregular and, in a preferred embodiment of the invention, extend from the projection 70 to a lower part of the housing.
FIG. 13 shows a housing 60 that has no protrusion 70 and has protrusions 130 on wall 62 extending substantially to the full height of housing 60. The external surface of wall 62 is relatively smooth but as a series of axially-spaced circumferentially spaced protrusions
130 at a circumferential edge of shoulder 70.
As with the plunger and cap mount rotational interlocking characteristic structures, the characteristic syringe barrel 14 interlocking and optional piston mount characteristic structure can be positioned alone on the plunger mount 12, alone on the syringe barrel 14 or have Cooperative structures in both plunger assembly 12 and syringe barrel 14.
It is also contemplated that a separate mechanism, device, or member may be used to interlock the two parts together to accomplish this purpose.
FIGS. 15-18 show various embodiments of the optional feature of interlocking rotationally moving plunger assembly 12 with respect to syringe barrel 14. In an embodiment shown in FIGS. 15-17 and 21 a fin 150 axially extended along an outer surface of the housing side wall 62 engages a tooth 152 positioned on an inner surface of the syringe barrel 14 at its proximal end 20. More preferably, the plunger assembly 12 will have more than one fin 150 with each fin being circumferentially spaced from each other. In an even more preferred form of the invention, the ^ ιφόΙφτΑ l ¡i-nu. '· I'Riai fins 150 spaced 90' .degrees from each other.
will have four
Furthermore, in a more preferred form of the invention, the syringe barrel will have a plurality of circumferentially spaced teeth 152. When the plunger assembly 12 is almost fully inserted into the syringe barrel 14, each of the fins 150 will extend on a tooth 152 to prevent rotation of the plunger assembly relative to syringe barrel 14.
FIG. 18 shows another embodiment of an interlocking feature to prevent rotation of the plunger assembly 12 with respect to the syringe barrel 14 and also prevents relative translational movement of the parts. In this embodiment, an annular protrusion 160 positioned on an inner surface of the syringe barrel at its proximal end 20 engages an annular retainer 162 on an external surface of the plunger rod.
FIGS. 19 and 20 show a plunger assembly equipped with antiseptic cap 12 and non-reflux syringe assembly 170. Non-reflux syringes are well known in the art and there are numerous methodologies for reducing reflux while accessing the access site of a central venous catheter. . In this embodiment, the annular projection 70 of the plunger assembly 12 abuts the projection 24 of the syringe barrel prior to the piston 50 making contact with a surface
30.
interior end wall
<img file="MX354573B_D0027.tif" />
INSTITUTE my Χ! 'Λ
I heard LA ΓΚΟΜ.Ι
IN »Ur» AlAL
Cap assembly is contemplated<sup>,,</sup>37ifi'i? Épt<sup>,</sup>The present invention need not be coupled or combined with a plunger or syringe barrel. FIGS. 22a-22b show a separate antiseptic cap assembly 200 having three circumferentially spaced ribs 120 for grasping by the hand of a cap assembly user. FIG. 22a shows cover 82 without absorbent material 86 and FIG. 22b shows the cover with an absorbent material. Cap 200 can be used for the same purposes of cap assembly 80 described above but will be used by hand. All other features of cap 200 are essentially the same as described with the exception that cap 200 does not have to be dimensioned to fit within a chamber carried by a syringe plunger. FIGS. 23 and 24 show varied frequency of ribs 120 and varied shapes and sizes.
FIG. 25 shows the cover 200 next to the access site 38 and FIGS. 26 and 27 show cover 200 coupled to access site 38.
A suitable absorbent material 86 includes medical-grade materials capable of storing and releasing an antiseptic liquid, or liquid having other medical purposes, and includes materials such as sponges, breakable ϊ Μ Ρ 4 capsules and other carraphic materials or devices á * dé “ to serve.
INiHl U1O M. X'Cv.Nú <> r · INDCSlkin p for this purpose. Suitable sponges may include any sponge suitable for use for medical purposes ~ * and may be naturally occurring or synthetic. The sponges can be die cut into suitable shapes or they can be molded into the desired shape. It is desirable for sponge 86 to bind to antiseptic cap 82 to prevent sponge 86 from inadvertently falling out of cap 82. FIG. 28 The sponge 86 is shown being captured between an annular wall 202 and a disk 204 attached to the lid 82 by any suitable method such as ultrasonic or vibrational welding or other techniques well known in the art.
FIGS. 29 and 30 show a variation on lid assembly 200 of FIG. 28. In this embodiment, the sponge is retained on the lid 82 with a plastic sheet 206 heat welded to the lid. In a preferred embodiment of the invention, the sponge is attached by an adhesive or by another method to form an assembly which is then attached to the cap.
FIGS. 31a-31b show cover 200 having a coaxially positioned and axially extended actuation post 220 circumferentially surrounded by a sponge 86 having a hole centrally positioned for attachment to post 220. FIG. 31a shows cover 200 in initial engagement with access site 38 and FIG. 31b shows the cap screwed into the access site 38 and the acting sponge post opens valve 39 and lets flow into the valve.
<img file="MX354573B_D0028.tif" />
The
FIGS. 32-34 show varied that, in a preferred embodiment of the invention, they were molded into an antiseptic sponge in various desirable shapes.
central opening to the lid and anticoagulant
230 for for
The sponge of FIG.
facilitate bonding by filling the sponge with other suitable fluids described above. FIG. 35 shows the lid a centrally placed power manager ultrasonic welder 232 which cooperates with the sponge in an ultrasonic power manager the manager sponges to the lid. FIG.
filled 240 antiseptic dispensing, that has a that has
231, one is put into coupling opposite sponge side
231.
energy shows lumen 242
244 in fluid anticoagulant communication or the like
Applying energy
231 a with for measured quantity of such fluid in the sponge portion.
melts and connects the device a head a source dispense interior of of of a the
FIG. 37 shows an alternative embodiment of antiseptic cap 200 where the sponge is replaced by antiseptic coating on actuation post 220.
the one
FIG. 38 shows the antiseptic cap 200 positioned in an ampoule container 233 prior to sealing the
or. JA. J.í.
- JMS-HTU ................. ...
ampoule container. V ·., ·?
FIG. 39 shows an antiseptic cap 300 with a threaded cap 302. The threaded cap 302 may be part of any of the antiseptic caps discussed herein. Threaded cover 302 is made of a deformable material capable of flexing under the application of moderate force applied by hand. In a preferred embodiment of the invention, the threaded cover 302 is made of a material-containing polymer and more preferably a polymeric material having a modulus of elasticity of less than 20,000 psi. In another preferred embodiment of the invention, the polymeric material will be an elastomer or plastomer or the like. Threaded cover 302 improves the connection between antiseptic cap 300 and a device such as a valve or other access devices 38. Threaded cover 302 provides a physical barrier to entry of pathogens, dust, or other contaminants through the splice threads of antiseptic cap 300 and the access device or valve to which it is attached. Threaded cover 302 also serves to retain antiseptic fluids from antiseptic cap 300 from leaking through the threads. The threaded cover can be made from a part of the antiseptic cap 300 using techniques well known in the art such as overmolding, or by bonding as a separate part using welding techniques such
<img file="MX354573B_D0029.tif" />
such as heat conductive heat welding, vibrational welding,
<img file="MX354573B_D0030.tif" />
adjustment by friction or stretching, or using a suitable adhesive.
The threaded cover 302 can provide a universal fit to most commercially available valves, connectors, and access devices, or the threaded cover 302 can be adapted to mate with a particular access device.
FIG. 39 shows, as described above, that antiseptic cap 300 has an annular wall 305 having a first end 306 and a second end 320 with the first end having a larger diameter diameter than the second end. The annular wall defines a central chamber 322 having an open end 323. In a preferred embodiment of the invention, chamber 322 will have a sponge 86 positioned therein as shown in FIG. 5 and 6 above, although not shown in FIG. 39. The threaded cover 302 is shown attached by an optional tie layer 304 to the first end 306 of the annular wall 305. The threaded cover 302 has a first support 308 and a second support 310. The first support 308 extends parallel to the annular wall 305 and the second support 310 extends radially internally of the annular wall 305 in a direction transverse to the first support 308 and through an open end portion 323 and defines an opening
<img file="MX354573B_D0031.tif" />
in chamber 322. The second with open end 323, bracket 310 ends in a
<img file="MX354573B_D0032.tif" />
distal end 330 with a rounded outer surface 332.
FIG. 40 shows an alternative embodiment of antiseptic cap 300 having threaded cover 302 having both first and second supports 308, 310 attached to first end 306 of annular wall 305 through tie layers 304a, b. A top surface 340 of the first end 306 is shown having the same diametrical thickness or dimension as the rest of the first end but it is contemplated that the top surface may have a radially extended shoulder 123 as shown in FIG. 5.
FIG. 41 shows an alternative embodiment of antiseptic cap 300 that differs from the antiseptic cap shown in FIGS. 39 and 40 but which does not include a reaming hole 336 shown in these figures. Reaming hole 336 provides a reduced diameter chamber and will therefore form a tighter fit with access devices with a narrower external diameter when compared to the cap shown in FIG. 41 which does not include the reaming hole. This is just one example of modifications that can be made to the geometry of the antiseptic cap to improve the connection between the cap and an access site.
<img file="MX354573B_D0033.tif" />
<img file="MX354573B_D0034.tif" />
FIGS. 42a-42b show rear antiseptic cap 300 with threaded cover
302 connected to a Cardinal SMART SITE 350 access site.
FIGS. 43a, b are perspective front and rear views of the antiseptic cap without the threaded cover 302 connected to the Cardinal SMART SITE access site.
FIGS. 44a-44b are front and rear perspective views of antiseptic cap 300 with threaded cover 302 connected to a Hospira access device (ICU) C1000 Key 352. FIGS. 45a, b are perspective front and rear views of the antiseptic cap, without a threaded cover 302, connected to the C1000 Key Hospira Access Device (ICU).
FIGS. 46a-46b are perspective front and rear views of antiseptic cap 300 with threaded cover 302 connected to a B. Braun ULTRASITE 354 access device. FIGS. 47a-47b are perspective front and rear views of the antiseptic cap without the threaded cover 302 connected to the B. Braun ULTRASITE access device.
FIGS. 48a-48b are perspective front and rear views of the antiseptic cap with threaded cover 302 connected to a Rymed INVISION PLUS 356 access device. FIGS. 49a-49b are perspective front and rear views of the antiseptic cap without the threaded cover: INSTITUTO MEJICANO .1 ·, ·
302 connected to a Ryfted access device
FIGS. 50-52 show various .Rs of the threaded cover 302. FIG. 50 differs from FIG. 51 because the second support 310 extends further through the opening of the chamber in FIG. 51 than that shown in FIG. 50. FIG. 52 shows another embodiment of the threaded cover 302 having a second segmented support 310a, b. This modality may be desirable to provide a more effective seal for certain access devices.
FIG. 53 shows an exploded view of an alternative embodiment 400 of the syringe barrel assembly.
10, discussed above, incorporating a cap fastener 402 in the parts system. Accordingly, the alternative mounting and system 400 has a jacketed 12 'plunger mount with cap holder and antiseptic cap, a syringe barrel 14, an antiseptic cap 82 (shown with optional screw cap 302), an absorbent material
86, and removable cover plate 68. FIG. 54 shows an exploded view of an antiseptic cap holder assembly 404 which includes the cap holder 402 with the antiseptic cap assembly 80 positioned within a chamber 406 of the cap holder 402. This embodiment 400 allows manufacture, assembly and sterilization. separate from mount 400 from plunger mount and syringe barrel.
Cap holder 402 has proximal and distal ends 408,
<img file="MX354573B_D0035.tif" />
412 and an external wall surface 414j ~ _ an opening 416 in chamber 406, and a radially externally extended projection 418 surrounding the opening 416 and extended proximal end 408 of cap holder 402. Cap holder 402 will also have a bottom wall optional 419.
In a preferred embodiment of the invention, cap holder 402 or antiseptic cap 82 will have a structure, member, or the like that prevents relative rotation of cap holder 402 and antiseptic cap 82 until antiseptic cap assembly 80 engages securely to the access device 38. Furthermore, in a preferred embodiment of the invention, the cap holder 402 or the plunger mount 12 'will have a structure, member, or the like to prevent relative rotation of the cap holder 402 and the plunger mount 12' until mounting Antiseptic cap 80 securely attaches to access device 38. Any of the anti-rotation devices discussed above to stop rotation of the antiseptic cap assembly 80 with the plunger mount 12 could be suitable for these purposes. Furthermore, it is contemplated that the devices discussed above with reference to the
FIGS. 15-21 to prevent relative rotation of plunger assembly 12 and syringe barrel 14 may be incorporated in this mode 400.
The
FIG. 53 shows that
<img file="MX354573B_D0036.tif" />
inner 412 of inner lid holder 100 and inner notches 108 that interact with outer ribs and outer notches 120, 122 of lid 82 as described above with respect to FIG. 5. These structures prevent or resist the relative rotation of cap holder 402 with respect to antiseptic cap assembly 80. The term ribs referred to herein are structures that are raised or extended out of a surface. The term notches refers to structures that extend below a surface or
<td>I know</td><td>define between two</td><td>ribbing</td><td>and</td><td>They are still</td><td colspan="2">lower level</td>
<td>than</td><td>the ribs.</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>FIG. 53</td><td>too</td><td colspan="2">shows a</td><td>structure</td><td>of</td>
<td colspan="2">interlocking for</td><td>to prevent</td><td>the</td><td>rotation</td><td>relative</td><td>of the</td>
cap fastener 402, or cap fastener assembly 404, relative to plunger assembly 12 '. The external wall surface
414 it has a plurality of circumferentially spaced and axially extended ribs 420 defining notches 424 between each pair of adjacent ribs.
In a preferred embodiment of the invention, the ribs
420 they are generally triangular in shape having a base portion 426 and a portion
Notches
424 are oppositely oriented triangularly shaped areas having notched base portions
430 spread between two portions
<img file="MX354573B_D0037.tif" />
<sub>z</sub> , INSTITUTE MU apex Q & e'w rnXJSTCjAL
<img file="MX354573B_D0038.tif" />
Adjacent 428 and apex notch portions 432 separating the adjacent rib base portions 426. On the inner wall surface 63 of the piston chamber 64 are similarly shaped piston ribs 434 and piston notches 436. The ribs 420 are sized to fit within plunger notches 436 and notches 424 are sized to fit and receive plunger ribs 434. Accordingly, when the cap holder 402 or the cap holder assembly 404 is inserted into the piston chamber 64 the cap holder ribs 420 interlock with the piston ribs 434 to prevent or resist the relative rotation of the clamp holder. cap 402, or cap holder assembly 404, with respect to plunger assembly 12 '.
In yet another preferred embodiment of the invention, the cap holder 402, the cap holder assembly 404 or the plunger assembly 12 'will have a structure, member or the like that resists the relative axial movement of these parts when the cap holder 402 or the cap fastener assembly 404 is fully positioned within the plunger assembly 12 '. In a preferred embodiment of the invention, the cap fastener 402 has an annular protrusion 440 that is dimensioned to fit within an annular groove 442 in the inner wall surface 414 of the; IMPI
MFXICaNO INSTITUTE. V top clip and preferably extend * ·.
plunger rib base ____ £ 34_<sub>or</sub>The portions are provided with a second interlocking structure having a plurality of teeth 450 which extend axially outwardly from the outer wall surface 414 of the cap holder and are positioned in the notches 424.
In a preferred embodiment of the invention, the teeth extend axially externally to a height beyond the height of the ribs 434.
The teeth 450 may be positioned in one or more of the notches or in each of the notches 424 or in alternate notches or, as shown, circumferentially spaced 90 ° from each other. The teeth 450 preferably are positioned in an intermediate portion, between the base and the apex, of a notch 424. The teeth 450 are sized to fit within a segmented annular groove 452 that extends circumferentially around the inner surface 412 that crosses through the plunger ribs 434 at an intermediate portion, between the base and the apex, of the rib ribs. plunger 434.
The
FIGS. 56a, 56b, 56c respectively show mounting 400 in a ready-to-use position, mated position and used position.
The montage
400 it is used in essentially the same way as described above with respect to FIGS. 3 and except that when mounting
400 the bra is in the worn position
ΙΆΊ
INjTJLj'l'Ti of cap 402 remains in plunger mount 12? ^;
The plunger is any material suitable for its purpose and includes glass and polymeric material. Suitable polymeric materials include, but are not limited to, homopolymers, copolymers, and terpolymers formed from monomers such as definas, cyclic olefins, amides, esters, and ethers. The polymeric material can be a mixture of more than one polymeric material and can be a monolayer structure or a multilayer structure. In a preferred embodiment of the invention, the syringe barrel and plunger are injection molded from a polypropylene material.
FIGS. 59-61 show a third embodiment 500 of a syringe barrel and plunger assembly equipped with antiseptic cap with antiseptic cap assembly 80 and cap plate 68 removed for clarity. The third embodiment 500 provides reconditioning of an antiseptic cap assembly 502 to a standard plunger 504. Antiseptic cap 502 has a first generally cylindrical outer wall 506 having a proximal end 508 and a distal end 510. Proximal end 508 is removably or fixedly attached to a button 512 of plunger 504. The proximal end has an opening 514 sized to fit around button 512 and has a member for attaching to the button. In a preferred embodiment of the invention, the joint member includes a circumferentially spaced
IMPI plurality iNrmde.M-.xicA ^ ep-güeta-á ^ DF LA FhOí ί £ Π <;) t '·. .. '' J i INDUfTpjAj and axially internally directed
516 extended from an inner wall surface 518 and the tabs engage a bottom surface of button 512 to attach antiseptic cap assembly 502 to plunger 504.
The distal end of antiseptic cap 504 has an upper annular protrusion 520 extending radially internally from the first cylindrical wall 506 and defines a generally circular opening 522. A second cylindrical wall 524 extends axially downward from the upper annular protrusion 520 and is positioned coaxially inside the first cylindrical wall 506. When antiseptic cap 504 is attached to plunger button 512 a lower peripheral edge of second cylindrical wall 524 will abut an upper surface of plunger button 512 capturing, by oppositely axially directed forces, plunger button 512 between tabs 516 and the second cylindrical wall. However, it is contemplated that a second set of tabs may be provided spaced axially away from the first set of tabs and piston button 512 may be trapped between the two sets of tabs. In addition, it is contemplated that other attachment means may be used that are well known in the art and the attachment member shown is exemplary only.
The second wall as shown with greater ribs and notches ii ivx rj \ i cylindrical 524 t
INDUSTRIAL xr ^ ii ·· ^ »· detail in FIG. 5 above with as described to engage antiseptic cap assembly 80 to prevent relative rotational movement and to resist relative axial movement of parts when antiseptic cap assembly 80 is fully inserted into the chamber. In addition, it is contemplated to adapt the plunger and syringe as described above to prevent or resist movement
<td>rotational relative</td><td>of the</td><td colspan="2">plunger with respect</td><td>to the</td><td>barrel.</td>
<td>The piston</td><td> 50</td><td>It can</td><td>form of</td><td>when</td><td>any material</td>
<td>suitable including</td><td>a</td><td>material</td><td>polymeric</td><td>or</td><td>a material of</td>
silicone. The plug can be selected from a material with a desired durometer so that the reflux is reduced when the plug engages an internal surface of the distal end wall of the syringe barrel.
Suitable blocking and rinsing solutions include a lower alcohol selected from ethanol, propanol, and butanol. The blocking solution can be a single lower alcohol or a mixture of lower alcohols.
Suitable blocking solutions can also include a lower alcohol with an antimicrobial and / or an anticoagulant. Suitable blocking solutions may contain at least one lower alcohol in a range from 1% to 99% by volume and at least one other anti-ax compound. ·· #. · .A. ·.
microbial and / or anticoagulant in
<img file="MX354573B_D0039.tif" />
INDUSTRIAL in volume. The lower alcohol will usually be an aqueous solution, typically 1% to 99% by volume, usually from
5% to 95% by volume. At least one other anti-microbial is selected from the group consisting of taurolidine and triclosan, and at least one anti-coagulant is selected from the group consisting of riboflavin, sodium citrate, ethylenediamine tetraacetic acid, and citric acid.
In a preferred embodiment of the invention, syringe assembly 10 will be pre-filled with one of the blocking solutions and will be packaged by a manufacturer and shipped to a healthcare provider. A cannula or needle will be attached to the distal end of the barrel and placed in fluid communication with the fluid access site of a permanent central venous catheter. The rinse solution will be injected into the catheter to clean or blog the catheter. Thereafter, the cap assembly 80 will be removed from the plunger 17 and the cap will be attached to the catheter fluid access site.
Antiseptic solutions containing citrate salt
In one form the antiseptic is a citrate salt solution and in another form of the invention the citrate salt solution is a hypertonic solution. The term hypertonic is used to refer to a fluid that has an osmotic concentration and density of the patient's blood.
The antiseptic solution preferably comprises a citrate salt with a concentration range, in weight percent, from about 1.5% to about 50% with an osmolality of about 300 to about 6400 mOsm. More preferably, the antiseptic solution comprises
<td>citrate salt</td><td>in</td><td>a</td><td>interval</td><td>of</td><td>concentration from</td>
<td>approximately</td><td> 10%</td><td>to</td><td colspan="2">approximately</td><td>40%, even more</td>
<td>preferably,</td><td>in</td><td>a</td><td>interval</td><td>of</td><td>concentration from</td>
approximately
30%.
approximately
20 a
In a preferred embodiment, the antiseptic solution is prepared to have a pH lower than that of the pH of the patient's blood. The citrate salt solution can be prepared to have a pH less than about
6.5, more preferably, from about 4.5 to about
6.5.
Furthermore, the citrate salt solution can include pharmaceutically acceptable agents such as sodium chloride and sodium heparin. The citrate salt solution can also include a variety of other antibacterial, antimicrobial, and anticoagulant agents such as gentamicin, vancomycin, and mixtures of these agents. Additional anticoagulant agents include, for example, heparin, urokinase, tissue plasminogen activation (tPA), and mixtures of these agents.
<img file="MX354573B_D0040.tif" />
Pharmaceutically acceptable, the citrate salt solution and the included salts and other additives which, within the scope of full medical judgment, are suitable for use in contact with human and lower animal tissues without toxicity, irritation, and undue allergic response . It is also typically necessary for a composition to be sterilized to reduce the risk of infection.
Antiseptic solutions containing antibacterial agent
An antiseptic solution containing antimicrobial agent of the present invention may contain at least one alcohol, at least one antimicrobial agent and at least one chelator and / or anticoagulant. Various antimicrobial substances as described herein, and which are well known to a person skilled in the art, can be combined with the blocking solution to inhibit infection. The antimicrobial blocking solution of the present invention can be used to fill or rinse a medical device such as a permanent device such as an implanted catheter. Other medical devices that are contemplated for use in the present invention are described herein.
In another preferred embodiment of the invention, the antiseptic agent may contain antibacterial agents such as those classified as ami ^ & Imoosix (iscusTr-iAL lactams, quinolones or sulfonamides, treptogramins,
<img file="MX354573B_D0041.tif" />
macrolides, fluoroquinolones, sulfametaxozoles, oxazolidinones tetracyclines, (such as linezolid), clindamycin, lincomycin, rifamycin, glycopeptides, polymyxins, lipopeptide antibiotics, as well as pharmacologically acceptable sodium salts, pharmacologically acceptable salts, lipid formulations, derivatives and / or analogues of the above.
Aminoglycosides are bactericidal antibiotics that bind the 30S ribosome and inhibit bacterial protein synthesis. They are typically active against aerobic gram-negative bacilli and staphylococci. Exemplary aminoglycosides that can be used in some specific aspects of the invention include amycin, kanamycin, gentamicin, tobramycin, or netilmycin.
Suitable beta lactams are selected from a class of antibacterials that inhibit bacterial cell wall synthesis. A majority of the clinically useful beta-lactams belong to either the penicillin group (penam) or cephalosporin groups (cefem). Beta-lactams also include carbapenems (eg, imipenem), and monobactams (eg, aztreonam). Beta-lactamase inhibitors such as clavulanic acid and its derivatives
<img file="MX354573B_D0042.tif" />
Institute *;
OF THE fT.
They are also included in this category.
Non-limiting examples of the penicillin group that can be used in the solutions of the present invention include amoxicillin, ampicillin, benzathine penicillin G, carbenicillin, cloxacillin, dicloxacillin, piperacillin, or ticarcillin, etc. Examples of cephalosporins include ceftiofur, ceftiofur sodium, cefazolin, cefaclor, ceftibuten, ceftizoxime, cefoperazone, cefuroxime, cefprozil, ceftazidime, cefotaxime, cepyrin, cepyrin, cefin, cefpirin, cefpirin, cefpirin, cefpirin, cefpirin, cefpirin, cefirin, cefirin, cefirin, cefirin etc.
Other examples of beta lactams include mipenem or meropenem which are extremely active parenteral antibiotics with a spectrum against almost all gram-positive and gram-negative organisms, both aerobic and anaerobic and to which Enterococci, B. fragilis, and P. aeruginosa are particularly susceptible.
Suitable beta lactamase inhibitors include clavulanate, sulbactam, or tazobactam. In some aspects of the present invention, antibacterial solutions may comprise a combination of at least one beta lactam and at least one beta lactamase inhibitor.
Macrolide antibiotics are another class of bacteriostatic agents that bind the 50S subunit of ribosomes and inhibit bacterial protein synthesis. These groups are active against anaerobic coconuts, with the exception
<img file="MX354573B_D0043.tif" />
of enterococci, and against gram-negative anaerobes. Exemplary macrolides include erythromycin, azithromycin, clarithromycin.
Quinolones and fluoroquinolones typically function for their ability to inhibit DNA gyrase activity. Examples include nalidixic acid, cinoxacin, trovafloxacin, ofloxacin, levofloxacin, grepafloxacin, trovafloxacin, sparfloxacin, norfloxacin, ciprofloxacin, moxifloxacin, and gatifloxacin.
Sulfonamides are synthetic bacteriostatic antibiotics with a broad spectrum against most gram-positive and many gram-negative organisms. These drugs inhibit the multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Examples include mafenid, sulfisoxazole, sulfamethoxazole, and sulfadiazine.
The group of tetracycline antibiotics includes tetracycline derivatives such as tigecycline which is a new investigational drug (IND), minocycline, doxycycline, or demeclocycline and analogs such as anhydrotetracycline, chlorotetracycline, or epioxytetracycline.
Suitable class of streptogtamine antibacterial agents include quinupristin, dalfopristin or the combination of two streptogramins.
DNA; <sup>1</sup> cwiTdtteeft—
Class drugs inhibit RNA polymerase-dependent suppression of RNA synthesis and have a very broad spectrum of activity against most gram-positive and gram-negative bacteria including Pseudomonas aeruginosa and Mycobacterium species. An exemplary rifamycin is rifampicin.
Other antibacterial drugs are glycopeptides such as vancomycin, teicoplanin, and derivatives thereof. Still other antibacterial drugs are polymyxins which are exemplified by colistin.
In addition to these various antibacterial agents such as prestinomycin, chloramphenicol, trimethoprim, fusidic acid, metronidazole, bacitracin, spectinomycin, nitrofurantion, daptomycin, other oritavancin, dalbavancin, ramaplamin, ketolide, etc. They can be used in the preparation of the antiseptic solutions described herein. Of these, metronidazole is active only against protozoa, such as Giardia lamblia,
Entamoeba histolytica and Trichomonas vaginalis, and strictly anaerobic bacteria.
Spectinomycin is a bacteriostatic antibiotic that binds to the 30S subunit of the ribosome, thus inhibiting the synthesis of bacterial protein and nitrofurantoin is used orally for the treatment or prophylaxis of UTI since it is active against species
IMPIOS 'USTITUTO MEXIC-. ·' T- <~ - 'Λ. pt u «οίιίϋΛϋ
Escherichia coli, Klebsíella-Enterobacter, stcfp ^ yipicocb ± -¡ ~ ^ and enterococci.
In other embodiments, the antimicrobial agent is an antifungal agent.
Some exemplary classes of antifungal agents include imidazoles or triazoles such as clotrimazole, miconazole, ketoconazole, econazole, butoconazole, omoconazole, oxyconazole, terconazole, itraconazole, fluconazole, voriconazole, posaconazole, ravuconazole, or flutrimazole;
polyene antifungals such as amphotericin
B, liposomal amphotericin, natamycin, nystatin lipid formulations nystatin; cell wall active cyclic lipopeptide antifungals, including echinocandins such as caspofungin, micafungin, anidulfungin, cylofungin; LY121019; LY303366;
the allylamine group of antifungals such as terbinafine.
Still other non-limiting examples of antifungal agents include naftifine, tonaphtate, mediocidin, candicidin, trichomycin, hamycin, aurefungin, ascosin, ayfatin, azacolutin, trichomycin, levorin, heptamycin, candimycin, griseofulvin, BF-796, BTF-796, BTF-796-MT, BT-796-MT6 , pradimicins (MNS
18184), benanomycin; ambisome; nikkomycin
Z, flucytosine, perimycin.
In another preferred embodiment of the invention, the antimicrobial agent is an antiviral agent. Non-limiting examples of antiviral agents include cidofovir,
IMPI
INSTITUTO .WC.HO
L> F LA FKCNLOAC industaiai ii> · ii zíC- · Τ *> χ - 1 r-Λ
.......
amantadine, rimantadine, acyclovir, ganciclovir, penciclovir, famciclovir, foscamet, ribavirin, or valciclovir. In some forms of the invention the antimicrobial agent is an innate immune protein or peptide. Some classes eg peptides of innate peptides or proteins are transerrins, lactoferrin, defensins, phospholipases, lysozyme, cathelicidins, serprocidines, proteins that increase bacteriocidal permeability, antipathetic helical alpha peptides, and other synthetic antimicrobial proteins.
In other embodiments of the invention, the antimicrobial agent is an antiseptic people. The various antiseptic agents are known in the art and these include a taurinamide derivative, a phenol, a quaternary ammonium surfactant, a chlorine containing agent, a quinaldinium, a lactone, a dye, a thiosemicarbazone, a quinone, a carbamate, urea, salicylamide, carbanilide, a guanide, an amidine, an imidazoline biocide, acetic acid, benzoic acid, ascorbic acid, propionic acid, boric acid, dehydroacetic acid, sulfurous acid, vanillic acid, p-hydroxybenzoic acid esters, isopropanol, propylene glycol, benzyl alcohol, chlorobutanol, phenylethyl alcohol, 2-bromo-2-nitropropan-l, 3-diol, formaldehyde, glutaraldehyde, calcium hypochlorite, potassium hypochlorite, sodium hypochlorite, iodine (in various solvents), povidone-iodine, hexamethylenetetramine, noxitholin, chloride
IMPI Yte
INSTITUTO MF.X'CánO -te. ·
Dt LA rxG ^ fr-Az c <sup>V</sup>
1- (3-chloroalyl) -3,5,7-triazo 1-azoniaadamantane, bc ^ Sb'lidrha<sup>1</sup>·, -Taurultam, N (5-nitro-2-furfuriliden) -1 - ami ηδ - Λ l'fl 3 Π t σί ira ·; '' nitro-2-furaldehyde, semicarbazone,
3,4,4'trichlorocarbanilide, 3,4 ', 5-tribromosalicylanilide, 3trifluoromethyl-4,4'-dichlorocarbanilide, 8-hydroxyquinoline, 1-cyclopropi1-6-fluoro-l, 4-dihydro-4-oxo-7 - (1piperazinyl) -3-quinolincarboxylic acid, 1,4-dihydro-l-ethyl6-fluoro-4-oxo-7- (1-piperazinyl) -3-quinolincarboxylic acid, hydrogen peroxide, peracetic acid, phenol, oxychlorose sodium, parachlorometaxylenol, 2,4,4'-trichloro-2'hydroxydiphenol, thymol, chlorhexidine, benzalkonium chloride, cetylpyridinium chloride, silver sulfadiazine, or silver nitrate.
In another preferred embodiment of the invention, the antiseptic solution includes a basic reagent and a stain. The basic reagent can be a guanidium compound, a
<td>biguanide,</td><td>a</td><td>bipyridine,</td><td>an antiseptic</td><td>phenoxide,</td><td>a</td><td>oxide</td>
<td>alkyl,</td><td>a</td><td>ar oxide</td><td>ilo, a thiol, a</td><td>halide,</td><td>a</td><td>amine</td>
<td>aliphatic,</td><td>or</td><td>an amine</td><td>aromatic. In</td><td>Some</td><td colspan="2">aspects</td>
specific, the basic reagent is a guanidinium compound. Non-limiting examples of guanidinium compounds include chlorhexidine, alexidine, hexamidine. In other specific modalities, the basic reagent is a bipyridine. An example of a bipyridine is octenidine. In still other aspects, the basic reagent is a phenoxide antiseptic.
TT Tx ID I jí M k A - i A
INSTITUTE y.'XiCA 'G - Λ ta ^ yW
The tint can be a tint of v.
monoazo dye, diazo dye, ia xanthene dye, anthraquinone dye, quinoline dye, FD&C dye. Non-limiting examples of triarylmethane dye include gentian violet, crystal violet, ethyl violet, or bright green.
Exemplary monazo dyes include FD&C
Yellow No.
5, or FD&C
Yellow
No.
Other non-limiting examples of FD&C stain include
blue
No.
o Green No.
3.
A non-limiting example of diazo dyes is
D&C Red No.
17.
An example of an indigoid dye is
FD&C Azul No. 2.
An example of a xanthene dye is FD&C Red No. 3; of an anthraquinone dye is
D&C Verde No. 6; and from a quinoline dye is D&C Yellow
NOT.
1.
Other examples of antiseptics that can be used for the solutions of the invention are phenoxide antiseptics such as clofoctol, chloroxylenol or triclosan. Still other antiseptic agents that can be used to prepare the antimicrobial solutions genlenol, genlosan, or genfoctol.
A person skilled in the art will appreciate that one or more antimicrobial agents can be used including one or more antibacterial agents, and / or one or more antifungal agents, and / or one or more antiviral agents, and / or one or more antiseptic agents, and / or combinations thereof.
A wide variety of
<img file="MX354573B_D0044.tif" />
contemplated as useful in the antiseptics of the invention, as free acid of EDTA, EDTA 2K, EDTA 2LÍ, ETA 2NH<sub>4</sub>, EDTA preparation of solutions This includes chelators such 2Na, EDTA 3Na, EDTA 4Na, EDTA 3K, Ba (II) -EDTA, Ca (II) -EDTA,
Dy (III) -EDTA,
Co (II) -EDTACu (II) -EDTA,
Eu (III) -EDTA, Fe (III) -
<td>EDTA,</td><td colspan="2">In (III) -EDTA,</td><td>The (III) -EDTA, CyDTA,</td><td>DHEG,</td><td>acid</td>
<td colspan="2">diethylenetriamin</td><td>penta</td><td>acetic (DTPA), DTPA-OH,</td><td>EDDA,</td><td>EDDP,</td>
<td>EDDPO,</td><td>EDTA-OH,</td><td>EDTPO,</td><td>EGTA, HBED, HDTA, HIDA,</td><td>GOING,</td><td>Methyl-</td>
<td>EDTA,</td><td colspan="3">NTA, NTP, NTPO, O-Bistren, TTHA,</td><td>EGTA,</td><td>DMSA,</td>
deferoxamine, dimercaprol, zinc citrate, a combination of bismuth and citrate, penicillamine, succimer or Etidronate. It is contemplated that any chelator which binds barium, calcium, cerium, cobalt, copper, iron, magnesium, manganese, nickel, strontium, or zinc will be acceptable for use in the present invention.
Alternatively, at least one anticoagulant such as heparin, hirudin, can be used.
EGTA, EDTA, urokinase, streptokinase, hydrogen peroxide, etc. in the preparation of the antimicrobial solutions of the invention.
In addition to the alcohols described above, a variety of alcohols are contemplated as useful in preparing the instant antiseptic solution, including any antimicrobially active alcohol. The
X. /. kp: '_TC
Say 1 /. HíCFIFCaü Y '-' -X Non-limiting examples of alcohols include etahbT;<sup>1Al</sup>me'taííe-t, isopropanol, propilenglicol, alcohol benci-iée ^^ eiwwbnt'aiTOd: -? - · 'phenylethyl alcohol, and the like.
A person skilled in the art will appreciate that the solutions of the current invention may comprise various combinations of at least one alcohol, at least one antimicrobial agent, and at least one chelator / anticoagulant.
In some specific embodiments, the solution of the invention comprises at least one alcohol, at least one tetracycline, and at least one chelator / anticoagulant. In a specific aspect, such an antimicrobial solution comprises ethanol, at least one tetracycline, and EDTA or heparin.
In other specific aspects, such a solution comprises ethanol, minocycline and EDTA or heparin. In one embodiment of this aspect, the minocycline concentration is
0.001 mg / ml to 100 mg / ml. In another embodiment, the minocycline concentration is approximately 3 mg / ml.
In another aspect, the EDTA concentration is in the range of 10-100 mg / ml. In one embodiment of this aspect, the EDTA concentration is approximately 30 mg / ml.
In another preferred embodiment of the invention, the antiseptic solution includes a sodium salt
<td>pharmacologically</td><td>acceptable,</td><td>a</td><td>Salt</td><td>of</td><td>calcium</td>
<td>pharmacologically</td><td>acceptable,</td><td>a</td><td>Salt</td><td>of</td><td>potassium</td>
<td>pharmacologically</td><td>acceptable and</td><td colspan="2">approximately</td><td>a</td><td>milligram</td>
IMPL
MEXICAN INSTITUTE per milliliter of polyhexamethylene hydrochloride ^ 'fógíían
<img file="MX354573B_D0045.tif" />
an aqueous mixture. Additionally, the eoluaion ... of the invention may also contain a pharmacologically acceptable salt of lactic acid.
Antiseptic solutions containing salt
A preferred antiseptic solution includes a pharmacologically acceptable sodium salt such as sodium chloride or the like in a concentration of between about 820 mg to about 900 mg, a pharmacologically acceptable calcium salt such as calcium chloride dihydrate or the like in a concentration between about 30.0 mg to about 36.0 mg, a pharmacologically acceptable potassium salt, such as potassium chloride or the like in a concentration between about 28.5 to about 31.5 mg and about one milligram per milliliter of polyhexamethylene biguanide hydrochloride in an aqueous mixture with about one hundred milliliters of water for injection USP For particular applications, the solution of the invention It can also include sodium lactate in a concentration between about 290 mg and about 330 mg in one hundred milliliters of aqueous mixture.
Photo-oxidant solutions
In another preferred embodiment of the present invention, the antiseptic solution contains an anticoagulant and a photo-oxidant. In certain modalities, a
N «··. '. · 2L: A f ..'> '-. ¾ ·, frOTfTi.TO' <Λ- - 4 photo-oxidant that has an antiseptic effect.<sup>OF</sup>e? * · herein, the term photo-oxidant nt is intended to_ refer to a compound (usually an organic dye) that has photo-oxidation properties, in which the compound exhibits increased oxidative potential on exposure to radiant energy such as light. The term photooxidant also refers to a composition that releases one or more electrons when struck by light.
In a preferred embodiment of the invention, the photo-oxidant is methylene blue, which advantageously provides antibiotic and antifungal activity, and also provides a color to make the antiseptic solution clearly identifiable. In addition to methylene blue, photo-oxidants can include Bengal rose, hypericin, methylene violet, proflavin, rivanol, acriflavin, toluene blue, trypan blue, neutral red, a variety of other dyes, and mixtures thereof. Therefore, in alternate aspects of the invention, one or more alternative photo-oxidants, preferably a colored photo-oxidant, is used in accordance with the invention instead of methylene blue.
Improved viscosity solutions
In another preferred embodiment of the invention, the antiseptic solution includes a low viscosity antibacterial agent mixed with an agent, INSTITUTO;.,. <sub>V</sub>JC<sub>YEAR</sub> . · '' From incTemaratc. '· Ae viscosity.
Examples of agents which can be used, in addition to those described above, comprise alcohols, chlorhexidine, chlorpactin, iodine, tauroline, citric acid, and soluble citric acid salts, particularly sodium citrate, optionally mixed with water.
Suitable viscosity increasing agents include Carbopol, starch, methyl cellulose, carboxypolymethylene, carboxymethyl cellulose, hydroxypropyl cellulose, or the like. Carbopol is a crosslinked polyacrylic acid based polymer sold by Noveon, Inc. It is preferably neutralized at about pH 7 with a base material such as tetrahydroxypropyl ethylene diamine, triethanolamine, or sodium hydroxide. Starch derivatives can also be used, such as hydroxyethyl starch, hydroxypropyl starch, or starch having bound organic acid groups, to improve compatibility with antibacterial agents such as alcohols, for example, ethanol or isopropanol. Such ester groups can be the reaction product of two to twelve carbon organic acids with starch, for example. In addition, the high-viscosity antiseptic solution can be created by the use of a fat emulsion, or other glycerol mono- or di-esters dispersions in water / alcohol of acids.
TM 'T
-L ·. 1 '·' UA> 'and fatty, or fatty acid esters of other ροϊΤδ ^ ι ^ ν /, ^^ - θ ^.' It conjugated sugars that have one or more linked fatty acid groups per molecule. Analogous compounds with ether linkages can also be used.
In addition, other materials such as alginic acid, with or without calcium citrate, or polyvinyl alcohol, with or without borax, povidone, polyethylene glycol alginate, sodium alginate, and / or tragacanth can be used. If desired, the fluid of this invention may also contain an effective amount of an antithrombogenic agent such as heparin, and a diluent such as water, along with other desired ingredients.
In a preferred embodiment of the invention, the antiseptic solution contains a mixture of isopropyl alcohol and neutralized Carbopol, with other optional ingredients being present such as water, antithrombogenic agents such as heparin, and the like. Preferably about 0.4 to 2 weight percent Carbopol is present. Citric acid may also be present as an antibacterial agent, either with or as a substitute for another antibacterial agent such as isopropyl alcohol or ethanol.
In another embodiment, the antiseptic solution is an isopropyl alcohol gel, optionally with up to about 30 weight percent water, and
<img file="MX354573B_D0046.tif" />
uo u ι ν ιν ν'- <sub>k</sub>. , sn. * Γ '' * '' J approximately 22 percent in<sup>OF</sup> hydroxypropylcellulose, to form a high-viscosity antiseptic solution.
In a further preferred embodiment of the invention, the antiseptic solution contains carbohydrates and / or glucose breakdown products. Such carbohydrates are chosen from the group of glucose and / or fructose. Suitable degradation products include 3-deoxyglucosone (3-DG), acetaldehyde, formaldehyde, acetaldehyde, glyoxal, methylglyoxal, 5-hydroxymethyl-2-furaldehyde (5-HMF), 2furaldehyde, and 3,4-dideoxyglucoson-3-ene (3,4-DGE).
Other suitable agents that are used in this embodiment of the antiseptic solution include substances that have anticoagulant properties, i.e. coagulation cascade inhibitors such as low and standard molecular weight heparin, fractionated heparin, synthetic coagulation cascade inhibitors, Futhan as a broad protease inhibitor, complexing and chelating substances such as citrate, EDTA,
EGTA, substances and mixtures used for the preservation of blood products (packages or plasma),
CDPA (citrate, sodium phosphate, dextrose, adenine), synthetic natural thrombin inhibiting substances.
Other suitable additives include fucosidan, riboflavin, vitamin E, alpha-tocopherol, folic acid, and amino acids.
Furthermore, anti-inflammatory compounds and drugs may also be used, for example
<img file="MX354573B_D0047.tif" />
sirolimus, tacrolimus and (MPA) and derivatives thereof, cyclosporine, diclofenac, etc.
Inhibitory peptides may also be used in the antiseptic solution such as defensins, (dermacidine), and others. Radicals, such as reactive oxygen species, NO or nitric oxide (NO) delivery system, and peroxynitrite can also be used. A buffer composition can also be included in the antiseptic solution, and in a preferred embodiment of the invention, the buffer contains lactate, bicarbonate, pyruvate, ethyl pyruvate and citric acid in combination and mixtures including pH adjustment by acetic acid, acid hydrochloric or sulfuric acid. In addition, additives that improve viscosity can be added, such as lipids or lipid substances (also to obtain water-insoluble vitamins or complexes in solution), nutrients with a high concentration density gradient, for example fluids containing amino acids, polyglucose, Icodextrin , pectin, hydroxyethyl starch (HES), alginate, hyaluronic acid, etc.
Taurolidine antiseptic solutions and gels
The antiseptic solutions of the present invention can include Taurolidine and / or Taurultam for elements can be combined with other antimicrobial agents. A gel with properties within the cap time interval modality of the present invention is a thixotropic to maintain the antiseptic solution and not spill during between uses. This is done by making a hydrogel matrix as a drug delivery vehicle containing biocompatible antimicrobial agent alone or with another active agent, which may be useful for particular purposes. The hydrogel matrix is biocompatible and biodegradable in the blood stream. The matrix may be a hydrogel (eg, pectin, gelatin, etc.), a protein (eg, collagen, hemoglobin, etc.), a colloidal substance (eg, serum albumin, etc.), an emulsion, or other adjuvant. Preferably, the matrix should have structural integrity and be thixotropic. Thixotropy is a property, which is exhibited by certain gels. It is a property characterized by a solid or semi-solid substance that when shaken, shaken, or subjected to high shear force becomes fluid and can flow and then returns to the semi-solid state when forces and motion stop. Alternatively, the gel may have the glue-like properties of the colloidal dispersion which resists movement, or flows until a high shear force is
IMPI Mexican Institute ·. -C. · Fluid and °<sup>F</sup> easily .
Gel can be used to provide other ingredients for the matrix for additional functional benefit. The preferred antimicrobial is Taurolidine, which can be added to the matrix as a microparticle powder, or encapsulated in liposomes, microspheres, or nanospheres. It should be appreciated that numerous active agents and drugs can be added to the thixotropic gel including sterilants, lysing agents (such as urokinase), image enhancers, catheter surface modifiers, antibiotics, and antimicrobial chemicals.
A hydrogel comprises a three-dimensional molecular network containing large amounts of water that gives it good biocompatibility with the consistency of material that is soft solid - as with the high diffusive properties for gases, chemicals and proteins. Suitable hydrogels include natural polymers including serum albumin, collagen, or alginates, polyvinyl alcohol, poly (ethylene oxide) or poly (hydroxyethylene), and polyelectrolytes, such as poly (acrylic acid), poly (styrene sulfonate), and carboxymethyl cellulose ( CMC).
A preferred embodiment of the antiseptic solution includes Tauroline with salicylic acid or sodium salicylate in an aqueous solvent. Salicylic acid and sodium salicylate are drugs that have been in catheters to improve
TM ip 7 ¿y. ·> ·.,
Jl .i. »1i .it :. : sa
MWKYNÜ INSTITUTE <· '·' '<£ * \ used with blbqueW ^^^ ÍJ' ^ rqSH ^^ ** biocidal action of the antibiotic alone and to inhibit the binding of microbes to surfaces.
This last attribute is especially important because the initiation of biofilm expression and growth requires that individual bacteria must first bind themselves to the fundamental surface. By stopping the binding, the biofilm formation is blocked.
Sodium salicylate has been shown to have remarkable antibiotic activity, including the ability to enhance the activities of certain antibodies. This drug inhibits the adherence, growth and biofilm formation.
Antiseptic solutions containing EDTA
<td>A solution</td><td>preferred antiseptic herein</td>
<td>invention provides</td><td>antimicrobial properties, anti-</td>
<td>fungal, antiviral</td><td>and anti-amoebic and they can also</td>
serve as an anti-coagulant. The salts and specific compositions of ethylene diamin tetraacetic acid (EDTA) (CioH<sub>12</sub>N<sub>2</sub>Na<sub>4</sub>08) are used at specified concentrations and pH levels.
The EDTA formulations of the present invention are safe for human administration and are biocompatible and non-corrosive. They can also have properties
Τ7 Τ. ζ'Ί '• Jí r' / A jt 1
INSTITUTO MEXICANO ΤΤ-T ~~ ££ · ί> Λ anticoagulants and therefore are useful and / or treat a variety of catheterized infections. In one embodiment, the antiseptic solutions of the present invention have at least four, and preferably at least five, of the following properties: inhibitory and / or bactericidal activity against a broad spectrum of bacteria in a planktonic form; inhibitory and / or fungicidal activity against a spectrum of fungal pathogens; inhibitory and / or bactericidal activity against a broad spectrum of bacteria in a sessile form; inhibitory activity against protozoal infections; inhibitory activity against Acanthamoeba infections; safe and biocompatible, at least in modest volumes, in contact with a patient; safe and biocompatible, at least in modest volumes, in a patient's blood stream; and safe and compatible with objects and industrial surfaces. The solution
<td>antiseptic</td><td>can</td><td>to have</td><td colspan="4">a pH greater than the physiological pH</td><td>such</td>
<td>like a pH</td><td>of> 8</td><td>. 0, or</td><td>yet</td><td>pH> 8.5,</td><td colspan="2">or at pH> 9, or</td><td>a</td>
<td>pH> 9.5.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>In</td><td>other</td><td colspan="2">modality</td><td>preferred</td><td>of the</td><td>invention,</td><td>the</td>
Antiseptic solution contains a sodium EDTA salt (or combination of sodium salts) in solution at a pH in the range between 8.5 and 12.5 and, in another embodiment, at a pH between 9.5 and 11.5 and, in yet another embodiment, at a pH of between 10.5 and 11.5.
When used herein
EDTA can refer to a single salt,
<img file="MX354573B_D0048.tif" />
such as di-sodium or tri-sodium or tetra-sodium salt, or another form of EDTA salt, or may refer to a combination of such salts.
The composition of EDTA salts depends both on the EDTA salts used to formulate the composition, and on the pH of the composition. For antiseptic solutions of the present invention consisting of sodium EDTA salts, and at the desired pH ranges (specified above), sodium EDTA salts are predominantly present in both the tri-sodium and tetra-sodium salt forms.
In one embodiment, the antiseptic solution contains a combination of at least the tri-sodium and tetrasodium salts of EDTA, and more preferably, the solutions containing at least 10% of EDTA in the composition are present in the tetra-salt form. sodium. In yet another embodiment, at least 50% and, more preferably at least 60%,
<td>EDTA in the</td><td>composition</td><td>this</td><td colspan="2">present in the form of</td><td>Salt</td>
<td>of tri-sodium.</td><td></td><td></td><td></td><td></td><td></td>
<td colspan="2">Solutions</td><td>EDTA</td><td>of</td><td>the present invention</td><td>are</td>
<td>preferably</td><td colspan="2">provided</td><td>in</td><td>sterile and</td><td>not</td>
Pyrogenic and can be packed in any convenient way.
The compositions can be prepared under sterile, aseptic conditions, or can be sterilized following preparation and / or packaging using any of a variety of yy, γ and j r techniques.
J. '. XVA) ». ! λ ..
sterilization
INDUS1 BAD
<img file="MX354573B_D0049.tif" />
The antiseptic formulation and production of compositions of the present invention is generally straightforward.
In one embodiment, the desired antiseptic solutions of the present invention are formulated by dissolving an aqueous solvent, such as desired water, and adjusting the pH to the desired pH. The solution sterilize using autoclave media, UV irradiation, or more EDTA salts in a purified, to concentration antiseptic EDTA salt solution can then be conventional, such as filtration and / or ultrafiltration, and other means. The preferred osmolarity range for EDTA solutions is from 240-500 mOsM / kg, more preferably from 300-420 mOsm / kg.
<td>The solutions are</td><td colspan="2">preferably</td><td>formulated</td><td>using</td>
<td>USP materials.</td><td></td><td></td><td></td><td></td>
<td>The solutions</td><td>antiseptics</td><td>than</td><td>they contain</td><td>you leave</td>
<td>different EDTA sodium</td><td>of salts of</td><td>tri-</td><td colspan="2">and tetra-sodium, such</td>
as disodium EDTA, they are also contemplated. For example, disodium EDTA solutions can be used but such solutions have a lower pH in solution than the desired pH range of the compositions of the present invention but, in adjusting the pH to the desired range using a setting material pH, such as sodium hydroxide, sodium acetate, and other well-known pH adjusting agents, EDTA solutions prepared using salts of f? i '· Jí Λ - .1 1 !. Λ r<sub>;</sub> . . ,. ,. ,,,. , at <STmiTO msxaca.no. And '·· di-sodium are converted to the combination DtiwieáiferhLclák:
• INDUSTRY !. TO EDTA solutions of di- and / or tri- and / or tetra-sodium salt of the present invention. Accordingly, different forms and combinations of EDTA salts can be used in the preparation of compositions of
EDTA of the present invention, provided that the pH of the composition is adjusted to the desired pH range prior to use. In one embodiment, antiseptic compositions consisting of a mixture of primarily tri- and tetra-sodium EDTA are provided by dissolving di-sodium EDTA in an aqueous solution, 3% -5% on a weight / volume basis, and adding hydroxide of sodium in a volume and / or concentration sufficient to provide the desired pH of> 8.5 and <12.0.
Antiseptic solutions containing antibacterial enzyme
Antibacterial enzyme refers to any proteolytic, pore-forming, degrading, or inhibitory enzyme that kills or damages a particular bacterial species or strain thereof. The result can be achieved by damaging the cell wall of bacteria, disrupting cell membranes associated with the cell wall or within bacteria, inhibiting protein synthesis within bacteria, disrupting the sugar skeleton, or by any other attributed mechanism to a peptide or protein considered by those skilled in the art to
<img file="MX354573B_D0050.tif" />
7Γ
INST is an antibacterial enzyme. The enzyme can be natural, wild type, modified - by conventional techniques, conjugated to other molecules, recombinantly expressed, or synthetically constructed.
An example of an antibacterial enzyme is lisostafin. Lisostafin is important because it is effective in the treatment of staphylococci and biofilms formed from them. Lisostafin and lisostafin analogs are defined as including lisostafin (wild-type), any mutant or variant of lisostafin, any recombinant, or related enzyme (analog) or any synthetic version or fragment of lisostafin (whether synthetic or otherwise) that retains the Proteolytic ability, in vivo and in vitro, to cleave crosslinked polyglycine bridges in staphylococcal cell wall peptidoglycan. Enzymes can be generated by post-translational processing of the protein (either by enzymes present in a producer strain or by enzymes or reagents introduced at any stage of the process) or by mutation of the structural gene. Mutations can include site deletion, insertion, domain removal, and replacement mutations.
Lysostafin can be synthetically constructed, expressed in mammalian cells, insects, bacteria, yeast, reptiles, or fungi, recombinantly expressed from a cell culture or larger recombinant species such as a mouse, or otherwise.
This could include
<img file="MX354573B_D0051.tif" />
T T. -7 i tt instituto mxicsno Vi -______ <· £> t úa i-ícitiuaü la dWffig't'ru synthetic activity retention incl JVüTidu <sup>1</sup> Pép Liidi.i ^ ... ^ ¿^.<sub>T</sub>. ^ synthetic polypeptides or recombinant expression of portions of the lisostafin enzyme responsible for its activity against staphylococci as part of a large protein or peptide, including chimeric proteins, that contain the active sites of one or more antibacterial enzymes that are effective against either staphylococci or other species of biofilm-forming bacteria.
Antibacterial enzymes can also be coated on the surface of the devices described herein by immersing the device in an enzyme solution for a sufficient length of time to form a biofilm inhibiting coating of the enzyme on the susceptible surface. . Even the smallest concentration of enzyme will confer some protection. Typically, a concentration of from about 10 pg / ml to about 100 mg / ml can be used. With device surfaces, coatings can also be formed by covalently binding the enzyme to them.
Antiseptic coatings
It is contemplated that the devices described herein can be coated with an antiseptic coating by any suitable technique such as immersing the part in an antiseptic solution, spraying the part with mixing the antiseptic solution by
<img file="MX354573B_D0052.tif" />
the antiseptic solution, or material in the polymeric material used to make the device.
amount added to metals include platinum,
In a preferred embodiment of the invention, a physiological, antimicrobial metal compound is resin to direct molding physiological, antimicrobial precious metals, such as an article. He understands them to be silver, gold, and copper and zinc. The physiological, antimicrobial metal compounds used herein include oxides and salts preferably of silver and also gold, for example: silver acetate, silver benzoate, silver carbonate, silver citrate, silver chloride, silver iodide, nitrate silver, silver oxide, silver sulfa diazine, silver sulfate, gold chloride and gold oxide. Platinum compounds such as chloropatinic acid or its salts (for example, sodium and calcium chloroplatinate) can also be used. In addition, the copper and zinc compounds can be used, for example, copper and zinc oxides and salts such as those indicated above for silver. Unique physiological metal antimicrobial compounds or combinations of physiological metal antimicrobial compounds can be used.
The preferred physiological metal compounds, antimicrobial, INSTITUTE μλχ-ca - O1 used in this 9Ltí ^^. I <5rk ^ .. spn<sub><ii</sub>¿?
silver acetate, silver oxide, sulfate, gold chloride and a combination of silver oxide and gold chloride.
The particles of the silver compounds are sufficiently capable of being extracted to form an inhibition zone to prevent and annihilate the growth of bacteria.
In another preferred embodiment of the invention, the devices herein are impregnated with triclosan and silver compounds or triclosan and chlorhexidine.
From the foregoing, it will be appreciated that numerous variations and modifications can be made without departing from the spirit and scope of the invention. It will be understood that no limitation with respect to the specific apparatus illustrated herein is intended or should be inferred. Of course, it is proposed to cover by the appended claims all modifications when they fall within the scope of the claims.
It is noted that in relation to this date, the best method known by the applicant to put the aforementioned invention into practice, is the one that is clear from the present description of the invention.
<img file="MX354573B_D0053.tif" />
<img file="MX354573B_D0054.tif" />
Contents10
70 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70
94 members in 13 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 11821190 | United States of America | – | |
| 82119007 | United States of America | A | |
| 12214526 | United States of America | – | |
| 21452608 | United States of America | A | |
| 11821190 | – | – | – |
| 12214526 | – | – | – |
| US20070821190 | – | – | – |
| US20080214526 | – | – | – |
Members94
| Document | Office | Kind | |
|---|---|---|---|
| US2008086091A1 | United States of America | A1 | |
| AU2008269133A1 | Australia | A1 | |
| BRPI0813497A2 | Brazil | A2 | |
| CA2692157A1 | Canada | A1 | |
| CA2846145A1 | Canada | A1 | |
| WO2009002474A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2009099529A1 | United States of America | A1 | |
| EP2167166A1 | European Patent Office (EPO) | A1 | |
| MX2010000171A | Mexico | A | |
| CN101801435A | China | A | |
| CO6270345A2 | Colombia | A2 | |
| HK1146813A | Hong Kong, China | A | |
| HK1146813A1 | Hong Kong, China | A1 | |
| US2011290799A1 | United States of America | A1 | |
| US8167847B2 | United States of America | B2 | |
| US2012109073A1 | United States of America | A1 | |
| US8231602B2 | United States of America | B2 | |
| US2012245531A9 | United States of America | A9 | |
| US2012283693A1 | United States of America | A1 | |
| US2012296284A1 | United States of America | A1 | |
| AU2012258435A1 | Australia | A1 | |
| NZ582395A | New Zealand | A | |
| US2013006194A1 | United States of America | A1 | |
| US2013023828A1 | United States of America | A1 | |
| US2013035667A1 | United States of America | A1 | |
| AU2013100345A4 | Australia | A4 | |
| CA2854296A1 | Canada | A1 | |
| WO2013066742A1 | World Intellectual Property Organization (WIPO) | A1 | |
| CN103191511A | China | A | |
| CN101801435B | China | B | |
| AU2013224680A1 | Australia | A1 | |
| AU2013100345B4 | Australia | B4 | |
| AU2008269133B2 | Australia | B2 | |
| NZ603404A | New Zealand | A | |
| CA2692157C | Canada | C | |
| AU2012332901A1 | Australia | A1 | |
| AU2012258435B2 | Australia | B2 | |
| MX2014005371A | Mexico | A | |
| NZ623138A | New Zealand | A | |
| CO7030941A2 | Colombia | A2 | |
| CN104023768A | China | A | |
| EP2773398A1 | European Patent Office (EPO) | A1 | |
| US8845593B2 | United States of America | B2 | |
| AU2014218397A1 | Australia | A1 | |
| JP2014532517A | Japan | A | |
| US2015018774A1 | United States of America | A1 | |
| US8968268B2 | United States of America | B2 | |
| EP2773398A4 | European Patent Office (EPO) | A4 | |
| NZ623139A | New Zealand | A | |
| NZ623141A | New Zealand | A | |
| HK1201770A | Hong Kong, China | A | |
| HK1201770A1 | Hong Kong, China | A1 | |
| NZ623136A | New Zealand | A | |
| US2015314119A1 | United States of America | A1 | |
| US9259535B2 | United States of America | B2 | |
| AU2013224680B2 | Australia | B2 | |
| NZ624449A | New Zealand | A | |
| CN103191511B | China | B | |
| CA2846145C | Canada | C | |
| AU2016219664A1 | Australia | A1 | |
| AU2014218397B2 | Australia | B2 | |
| MX345307B | Mexico | B | |
| JP6087364B2 | Japan | B2 | |
| CN104023768B | China | B | |
| BR112014010805A2 | Brazil | A2 | |
| US9700676B2 | United States of America | B2 | |
| US9700677B2 | United States of America | B2 | |
| US9700710B2 | United States of America | B2 | |
| US9707348B2 | United States of America | B2 | |
| US9707349B2 | United States of America | B2 | |
| US9707350B2 | United States of America | B2 | |
| AU2012332901B2 | Australia | B2 | |
| US2017361023A1 | United States of America | A1 | |
| EP2167166A4 | European Patent Office (EPO) | A4 | |
| MX354573BThis record | Mexico | B | |
| AU2016219664B2 | Australia | B2 | |
| US10328207B2 | United States of America | B2 | |
| EP2167166B1 | European Patent Office (EPO) | B1 | |
| US2020121858A1 | United States of America | A1 | |
| CA2854296C | Canada | C | |
| ES2808632T3 | Spain | T3 | |
| BRPI0813497B1 | Brazil | B1 | |
| US2021093791A1 | United States of America | A1 | |
| BRPI0813497B8 | Brazil | B8 | |
| BR112014010805B1 | Brazil | B1 | |
| US11160932B2 | United States of America | B2 | |
| EP2773398B1 | European Patent Office (EPO) | B1 | |
| US11229746B2 | United States of America | B2 | |
| ES2907323T3 | Spain | T3 | |
| US2022379035A1 | United States of America | A1 | |
| US2022401652A1 | United States of America | A1 | |
| US11684720B2 | United States of America | B2 | |
| US12042640B2 | United States of America | B2 | |
| US2025099686A1 | United States of America | A1 |
Numbers
- Publication
- 354573
- Publication, DOCDB
- 354573
- Publication, EPODOC
- MX354573
- Application
- 2013006175
- Application, DOCDB
- 2013006175
- Application, EPODOC
- MX20130006175
Titles
- Spanish
- TAPA ANTISEPTICA CON CUBIERTA ROSCADA.
Classification
- CPC, 12
- A61M5/31511
- A61M5/002
- A61M5/3135
- A61M5/3137
- A61M5/347
- A61M39/02
- A61M39/16
- A61M39/162
- A61M39/20
- A61M2005/3104
- A61M2005/31506
- A61M2039/1033
- IPC, 1
- A61M5 00